Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 655,096
  • Shares Outstanding, K 108,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,200 K
  • 36-Month Beta 0.85
  • Price/Sales 28.13
  • Price/Cash Flow N/A
  • Price/Book 22.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.06
  • Number of Estimates 4
  • High Estimate -0.04
  • Low Estimate -0.10
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.86 +22.71%
on 07/31/18
6.29 -5.09%
on 08/14/18
+0.38 (+6.80%)
since 07/13/18
3-Month
3.21 +85.98%
on 05/16/18
7.21 -17.20%
on 07/09/18
+2.72 (+83.69%)
since 05/15/18
52-Week
0.94 +535.11%
on 08/21/17
7.21 -17.20%
on 07/09/18
+4.92 (+468.57%)
since 08/15/17

Most Recent Stories

More News
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain

Medical-Drugs Stock Outlook: No Respite from Near-Term Pain

RDHL : 6.05 (+0.83%)
ARQL : 5.97 (-0.83%)
AERI : 63.60 (-3.27%)
GLMD : 11.28 (+1.08%)
ArQule (ARQL) Beats Q2 Earnings and Revenue Estimates

ArQule (ARQL) delivered earnings and revenue surprises of 150.00% and 78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

ARQL : 5.97 (-0.83%)
ArQule Reports Second Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2018.

ARQL : 5.97 (-0.83%)
Is Exelixis (EXEL) Poised for a Beat Again in Q2?

Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates....

ARQL : 5.97 (-0.83%)
EXEL : 19.41 (-2.36%)
RHHBY : 29.9400 (-0.89%)
BMY : 60.26 (+0.50%)
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.

ARQL : 5.97 (-0.83%)
LLY : 103.33 (+0.87%)
INCY : 66.87 (+0.63%)
NVS : 81.83 (-0.38%)
Has ArQule (ARQL) Outpaced Other Medical Stocks This Year?

Is (ARQL) Outperforming Other Medical Stocks This Year?

ARQL : 5.97 (-0.83%)
ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018. The Company will hold...

ARQL : 5.97 (-0.83%)
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their...

ARQL : 5.97 (-0.83%)
Free Pre-Market Technical Recap on ArQule and Three Additional Biotech

Stock Research Monitor: ARNA, ARWR, and ATRA

ARQL : 5.97 (-0.83%)
ARNA : 35.80 (-2.95%)
ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.50 per share. ArQule has...

ARQL : 5.97 (-0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 6.34
1st Resistance Point 6.15
Last Price 5.97
1st Support Level 5.75
2nd Support Level 5.54

See More

52-Week High 7.21
Last Price 5.97
Fibonacci 61.8% 4.81
Fibonacci 50% 4.07
Fibonacci 38.2% 3.34
52-Week Low 0.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar